Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Strange trades its as if wanted at all cost to buy , apart from that have not got a clue why it jumped price
Adam
Agree
Maybe news on the way
Fingers crossed
Interesting finish
This was a bit of a condescending piece of drivel in response that I had to read, which did little to respond to the legitimate challenge raised. Cheers for the pat on the head but I kind of figured this was not Bitcoin you twat.
Have you gone walkies till end of March? :-)
Notaflipper:
It's only a month since Alora, the parent company of Avion, invested £1.2 in IMM. This looked to me to be an important signal that IMM's American partner in the PK Study and the Lupuzor P3 trial was seriously supportive of IMM and its science.
Pharma research is different from Bitcoin so don't expect day by day changes in outlook - and it's not about Eureka moments. Waiting until the end of March for the all-important PK Study results is not too much to ask, is it?
Nope I would not agree with that, and still feel an update should be forthcoming. LTHs have had to put it mildly a torrid few years, and 2021 was by all accounts a write-off year as the Company re-organised itself and cut down their product portfolio. Indeed there was a revised timeline issued for the Lupuzor issued in February. So although the November RNS did explain in detail the timeline for the Lupuzor PK study delivering in Q1 2022 and moving into Phase 3 thereafter, some given the narrative would have expected the business to provide reassurance to the market between November and March that everything was on track. Although I am sure that the scientists would just love to shut themselves in a lab and get on with it, but the CEO should know that the reason for the current sp so close to P3 trials is due to past narrative here and why he is now expected to provide better reassurance to the markets.
But as I say although the November RNS did cover the timescales of Lupuzor PK study and Phase 3 trials, the subscription for 11M shares by Alora Pharmaceuticals LLC, the parent company of Avion Pharmaceuticals LLC at the premium price of 11p, was explained to be the depth of the product portfolio aside from Lupuzor where commercialisation opportunities should be updated to the market after a year of consolidation. So although it is appreciated that the BioAMB clinical studies are ongoing in H1 2022, shareholders could be be forgiven for an update to commercial partnering discussions with the two potential commercial partners given the Boards stated commitment "to enter into collaborative commercial partnerships, as early as possible, with each product in the portfolio". This is not pleading, more an expectation that this should be forthcoming to explain to the market the premium price paid in the placing.
A good post, easy to forget the timescales. Optimistic that 2022 will be a better year.
Thanks , good to see a review
Long term on this company for 5 years anyway
Some of our contributors are pleading for news from Tim to give us reassurance and to boost the SP. But if you look back to the update on the research programme that was detailed in the RNS of 18th November, 2021, it was clear that we could not expect much news until the completion of the PK Study at the end of March - so another 2 months to wait. The most we are likely to hear now is confirmation that the volunteers on the Study have all been dosed.
Beyond March, we should then hear that two very important trials have been started: Lupuzor Phase 3 and CIDP Phase 2/3. Maybe also news on BioAMB including on whether a partner has come forward to co-finance the research programme. Maybe also a similar announcement in the case of CIDP.
So, sorry to relate, this is likely to be a no-news period until the end of March. I would love to be proved wrong!